05-21-04

S/N 09/546,857

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Cunningham et al.

Examiner:

Spector, Lorraine

Serial No.:

09/546,857

Group Art Unit:

1647

Filed:

April 10, 2000

Docket No.:

11669.0114USU1

Title:

VASCULAR ENDOTHELIAL CELL GROWTH FACTOR VARIANTS

AND USES THEREOF

CERTIFICATE UNDER 37 CFR 1.6(d):

FROM-Merchant & Gould

I hereby certify that this paper is being transmitted by facsimile to the Commissioner for Patents, U.S. Patent and

Trademark Office, on May 21, 2004 at facsimile number 703.872.9306.

REQUEST FOR CONTINUED EXAMINATION UNDER 37 C.F.R. §1.114

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Under 37 C.F.R. §1.114, it is respectfully requested that this application be accorded the benefits of Continued Examination.

Please charge Deposit Account No. 13-2725 in the amount of \$770.00 to cover the required fee for a large entity.

Respectfully submitted,

MERCHANT & GOULD P.C.

P.O. Box 2903

Minneapolis, MN 55402-0903

ettelber

612/332-5300

Denise Kettelberger Reg. No. 33,924

DMK:EED:lek

23552

FROM-Merchant & Gould

RECEIVED CENTRAL FAX CENTER

MAY 2 1 2004

RESPONSE UNDER 37 C.F.R. 1.116 EXPEDITED PROCEDURE **EXAMINING GROUP 1647**

S/N 09/546,857



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Cunningham et al.

Examiner:

Spector, Lorraine

Serial No.:

09/546,857

Group Art Unit:

1647

Filed:

April 10, 2000

Docket No.:

11669.114USU1

Confirmation No.: 3105

Title:

VASCULAR ENDOTHELIAL CELL GROWTH FACTOR VARIANTS

AND USES THEREOF

CERTIFICATE UNDER 37 CFR 1.6(d):

I hereby certify that this paper is being transmitted by facsimile to the U.S. Partit and Trademark Office on May 21, 2004,

at 703.872.9306.

AMENDMENT UNDER 37 C.F.R. § 1.116

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Final Office Action dated January 21, 2004, the date for timely reply extended to May 21, 2004, Applicants respectfully request entry and consideration of the following amendment and remarks. No issues not previously considered by the Examiner are raised herein.

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks begin on page 8 of this paper.